Antiangiogenic agent and Immunomodulator

This page covers all Antiangiogenic agent and Immunomodulator drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting VEGF.

Targets

VEGF

Phase 2 pipeline (1)

• Avastin in combination with Roferon-A · Central European Society for Anticancer Drug Research · Oncology
  Avastin (bevacizumab) inhibits angiogenesis by binding to vascular endothelial growth factor (VEGF), while Roferon-A (interferon alfa-2a) modulates the immune response and has antiproliferative effects.

Patent intelligence

• antiangiogenic agent and immunomodulator patent landscape — aggregated cliff calendar, attackable patents, originator estates